[HTML][HTML] The Role of Galectin-3 in Predicting Congenital Heart Disease Outcome: A Review of the Literature
A Făgărășan, M Săsăran, L Gozar, A Crauciuc… - International Journal of …, 2023 - mdpi.com
Galectin-3 (Gal-3) is a novel pro-fibrotic biomarker that can predict both right and left cardiac
dysfunction caused by various cardiovascular conditions. Its expression seems to be …
dysfunction caused by various cardiovascular conditions. Its expression seems to be …
Atrial Fibrillation Ablation in Congenital Heart Disease: Therapeutic Challenges and Future Perspectives
A Baroutidou, N Otountzidis… - Journal of the …, 2024 - Am Heart Assoc
The increasing prevalence of atrial fibrillation (AF) in adults with congenital heart disease
raises significant questions regarding its management. The unique underlying anatomic and …
raises significant questions regarding its management. The unique underlying anatomic and …
Comparison of serum biomarkers of myocardial fibrosis with cardiac magnetic resonance in patients operated for tetralogy of Fallot
MP DiLorenzo, G DeCost, AD Mai, N Hughes… - International journal of …, 2022 - Elsevier
Background Serum biomarkers of myocardial fibrosis are considered markers of adverse
outcome in adults with heart disease. Associations between biomarkers and clinical …
outcome in adults with heart disease. Associations between biomarkers and clinical …
[HTML][HTML] Overcoming Underpowering in the Outcome Analysis of Repaired—Tetralogy of Fallot: A Multicenter Database from the CMR/CT Working Group of the Italian …
L Ait-Ali, B Leonardi, A Alaimo, G Baccano, E Bennati… - Diagnostics, 2023 - mdpi.com
Background: Managing repaired tetralogy of Fallot (TOF) patients is still challenging despite
the fact that published studies identified prognostic clinical or imaging data with rather good …
the fact that published studies identified prognostic clinical or imaging data with rather good …